KennethHandeMD

PubMed

• 12 citations
  In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous
  Mongkon Charoenpitakchai, Eric Liu, Zhiguo Zhao, Tatsuki Koyama, Won Jae Huh, Jordan Berlin, Kenneth R. Hande, Ronald C. Walker, Chanjuan Shi> ;Virchows Archiv. 2017 Feb 17
• 58 citations
  Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors.
  Chanjuan Shi, Raul S. Gonzalez, Zhiguo Zhao, Tatsuki Koyama, Toby C. Cornish, Kenneth R. Hande, Ronald C. Walker, Martin P. Sandler, Jordan Berlin, Eric Liu> ;American Journal of Clinical Pathology. 2015 Mar 1
• Bone cancer.
  Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerso...> ;J Natl Compr Canc Netw. 2013-06-01
• 30 citations
  Signal transduction pathway analysis in desmoid‐type fibromatosis: Transforming growth factor–β, COX2 and sex steroid receptors
  Nicholas A. Mignemi, Doha Itani, John H. Fasig, Vicki L. Keedy, Kenneth R. Hande, Brent W. Whited, Kelly C. Homlar, Hernan Correa, Cheryl M. Coffin, Jennifer O. Black,...> ;Cancer Science. 2012 Dec 1
• 4 citations
  Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases ☆
  Justin M M Cates, Jennifer O. Black, Doha Itani, John H. Fasig, Vicki L. Keedy, Kenneth R. Hande, Brent W. Whited, Kelly C. Homlar, Jennifer L. Halpern, Ginger E. Holt...> ;Human Pathology. 2012 Oct 1
• 10 citations
  Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy
  Justin M M Cates, Jennifer O. Black, Carmen C. Wolfe, Eric T. Shinohara, Ginger E. Holt, Vicki L. Keedy, Kenneth R. Hande, Kelly C. Homlar, Jennifer L. Halpern, Herber...> ;Human Pathology. 2012 Sep 1
• 3 citations
  Nuclear p63 expression in osteoblastic tumors
  Michael E. Kallen, Melinda E. Sanders, Adriana Gonzalez, Jennifer O. Black, Vicki L. Keedy, Kenneth R. Hande, Kelly C. Homlar, Jennifer L. Halpern, Ginger E. Holt, Her...> ;Tumour Biology. 2012 May 25
• Racial differences in the pattern of hematologic toxicity in the treatment of colorectal cancer.
  Oluwole OO, Wu W, Wolff SN, Hande KR> ;J. Clin. Oncol.. 2012-02-01
• 399 citations
  Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results ...
  George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Blay Jy, Kenneth R. Hande, Mary L. Keohan, Brian L. Samuels, Scott M. Schuetz...> ;Journal of Clinical Oncology. 2009 Sep 1
• 6 citations
  Developing an In-Training Examination for Fellows: The Experience of the American Society of Clinical Oncology
  Frances A. Collichio, Karen M. Kayoumi, Kenneth R. Hande, Richard E. Hawkins, Janine L. Hawley, David J. Adelstein, Jean M. D'Angelo, James A. Stewart> ;Journal of Clinical Oncology. 2009 Apr 1
• 68 citations
  The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study
  Kenneth R. Hande, Anne E. Hagey, Jordan Berlin, Yingna Cai, Kysa Meek, Hiro Kobayashi, A. Craig Lockhart, Diane Medina, Jeffrey A. Sosman, Gary Gordon, Mace L. Rothenberg> ;Clinical Cancer Research. 2006 May 1
• 19 citations
  Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer
  Albert C. Lockhart, Gillian F. Cropp, Jordan Berlin, Edwin F. Donnelly, Robert D. Schumaker, Larry J. Schaaf, Kenneth R. Hande, Arthur C. Fleischer, Alison L. Hannah, ...> ;American Journal of Clinical Oncology. 2006 Apr 1
• 51 citations
  Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
  Peter Nygren, Kenneth R. Hande, Kevin J. Petty, Margaret Fedgchin, Kristien Van Dyck, Anup K. Majumdar, Debbie Panebianco, Marina De Smet, Tuli Ahmed, M. Gail Murphy, ...> ;Cancer Chemotherapy and Pharmacology. 2005 Feb 19
• 7 citations
  Topoisomerase II inhibitors.
  Kenneth R Hande> ;Cancer Chemotherapy and Biological Response Modifiers. 2003 Jan 1
• An open-label, balanced, 2-period crossover study to investigate the influence of aprepitant on docetaxel pharmacokinetics.
  Hande K, Nygren P, Fedgchin M, Vandyck K, Majumdar A, Panebianco D, Petty K, Sjolund M, Cocquyt V, Vanbelle S> ;J. Clin. Oncol.. 2004-07-15
• Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily × 7 every 3 weeks.
  Kobayashi H, Hande KR, Berlin JD, Roth BJ, Sosman JA, Lockhart AC, Hagey A, Meek K, Coates A, Rothenberg ML> ;J. Clin. Oncol.. 2004-07-15
• A phase I trial of an anti-pka oligonucleotide (GEM231) administered with weekly CPT-11.
  Lockhart AC, Rudin CM, Berlin JD, Roth BJ, Hande KR, Martin RR, Sullivan TM, Grindel JM, Zhang R, Rothenberg ML> ;J. Clin. Oncol.. 2004-07-15
• 33 citations
  Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor.
  Kenneth R. Hande, Mary Collier, Linda Paradiso, Jill Stuart-Smith, Mary Dixon, Neil J. Clendeninn, Geoff Yeun, D. Alberti, Kim Binger, George Wilding> ;Clinical Cancer Research. 2004 Feb 1
• 15 citations
  A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors
  A. Craig Lockhart, Martin Howard, Kenneth R. Hande, Bruce J. Roth, Jordan Berlin, Franzanne Vreeland, Angela Campbell, Erminia Fontana, Francesca Fiorentini, Fowst Cam...> ;Clinical Cancer Research. 2004 Jan 15
• 36 citations
  Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt...
  Hak Choy, Russell F. DeVore, Kenneth R. Hande, Lester Porter, Paul Rosenblatt, B. Slovis, K. Laporte, Yu Shyr, David H. Johnson> ;Lung Cancer. 2001 Dec 1
• 44 citations
  A randomized Phase II trial in patients with carcinoma of an unknown primary site.
  Jonathan E. Dowell, Audrey M. Garrett, Yu Shyr, David H. Johnson, Kenneth R. Hande> ;Cancer. 2001 Feb 1
• 204 citations
  Chromosome 19 Translocation, Overexpression of Notch3, and Human Lung Cancer
  Thao P. Dang, Adi F. Gazdar, Arvind K. Virmani, Tanya Sepetavec, Kenneth R. Hande, John D. Minna, John Roberts, David P. Carbone> ;Journal of the National Cancer Institute. 2000 Aug 16
• 80 citations
  A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Ce...
  Hak Choy, Russell F. DeVore, Kenneth R. Hande, Lester Porter, Paul Rosenblatt, Furhan Yunus, Larry Schlabach, Clyde Smith, Yu Shyr, David H. Johnson> ;International Journal of Radiation Oncology, Biology, Physics. 2000 Jul 1
• 6 citations
  Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
  Brenda P. Nicholson, David M. Paul, Kenneth R. Hande, Yu Shyr, Michael Meshad, Alan Cohen, David H. Johnson> ;Clinical Breast Cancer. 2000 Jul 1
• 21 citations
  A Phase I Trial of Outpatient Weekly Docetaxel and Concurrent Radiation Therapy for Stage III Unresectable Non–Small-Cell Lung Cancer: A Vanderbuilt Cancer Center Affi...
  Hak Choy, Russell F. DeVore, Kenneth R. Hande, L.L. Porter, P.A. Rosenblatt, B. Slovis, K. Laporte, Yu Shyr, David H. Johnson> ;Clinical Lung Cancer. 2000 Apr 1
• Join now to see all